Biofrigas Sweden Valuation
Is BIOF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BIOF's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIOF's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOF?
Other financial metrics that can be useful for relative valuation.
What is BIOF's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | kr6.75m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BIOF's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1x | ||
TRIBO B Triboron International | 0.4x | n/a | kr29.0m |
BIOGAS Biokraft International | 1.9x | n/a | kr880.3m |
PRGS Progres a.d | 1.6x | n/a | дин42.8m |
8347 F8 Enterprises (Holdings) Group | 0.03x | n/a | HK$11.0m |
BIOF Biofrigas Sweden | 1.9x | n/a | kr6.8m |
Price-To-Sales vs Peers: BIOF is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1x).
Price to Earnings Ratio vs Industry
How does BIOF's PE Ratio compare vs other companies in the European Oil and Gas Industry?
Price-To-Sales vs Industry: BIOF is expensive based on its Price-To-Sales Ratio (1.9x) compared to the European Oil and Gas industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is BIOF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIOF's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.